Research and Development Expense of PharmaCyte Biotech, Inc. from 30 Apr 2013 to 31 Oct 2025

Taxonomy & unit
us-gaap: USD
Description
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
Summary
PharmaCyte Biotech, Inc. quarterly and annual Research and Development Expense in USD history and change rate from 30 Apr 2013 to 31 Oct 2025.
  • PharmaCyte Biotech, Inc. Research and Development Expense for the quarter ending 31 Oct 2025 was $141,085, a 45% increase year-over-year.
  • PharmaCyte Biotech, Inc. Research and Development Expense for the twelve months ending 31 Oct 2025 was $481,172, a 16% increase year-over-year.
  • PharmaCyte Biotech, Inc. annual Research and Development Expense for 2024 was $438,416, a 7.6% increase from 2023.
  • PharmaCyte Biotech, Inc. annual Research and Development Expense for 2023 was $407,431, a 13% decline from 2022.
  • PharmaCyte Biotech, Inc. annual Research and Development Expense for 2022 was $468,536, a 32% decline from 2021.
Source SEC data
View on sec.gov
Research and Development Expense, Trailing 12 Months (USD)
Research and Development Expense, Quarterly (USD)
Research and Development Expense, YoY Quarterly Change (%)
Research and Development Expense, Annual (USD)
Research and Development Expense, YoY Annual Change (%)

PharmaCyte Biotech, Inc. Quarterly Research and Development Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $481,172 $141,085 +$43,615 +45% 01 Aug 2025 31 Oct 2025 10-Q 18 Dec 2025 2026 Q2
Q2 2025 $437,557 $95,157 -$859 -0.9% 01 May 2025 31 Jul 2025 10-Q 15 Sep 2025 2026 Q1
Q1 2025 $438,416 $126,734 +$32,551 +35% 01 Feb 2025 30 Apr 2025 10-K 11 Aug 2025 2025 FY
Q4 2024 $405,865 $118,196 -$8,536 -6.7% 01 Nov 2024 31 Jan 2025 10-Q 17 Mar 2025 2025 Q3
Q3 2024 $414,401 $97,470 +$15,437 +19% 01 Aug 2024 31 Oct 2024 10-Q 18 Dec 2025 2026 Q2
Q2 2024 $398,964 $96,016 -$8,467 -8.1% 01 May 2024 31 Jul 2024 10-Q 15 Sep 2025 2026 Q1
Q1 2024 $407,431 $94,183 +$8,309 +9.7% 01 Feb 2024 30 Apr 2024 10-K 11 Aug 2025 2025 FY
Q4 2023 $399,122 $126,732 +$81,339 +179% 01 Nov 2023 31 Jan 2024 10-Q 17 Mar 2025 2025 Q3
Q3 2023 $317,783 $82,033 -$95,963 -54% 01 Aug 2023 31 Oct 2023 10-Q 13 Dec 2024 2025 Q2
Q2 2023 $413,746 $104,483 -$54,790 -34% 01 May 2023 31 Jul 2023 10-Q 17 Sep 2024 2025 Q1
Q1 2023 $468,536 $85,874 -$168,191 -66% 01 Feb 2023 30 Apr 2023 10-K 13 Aug 2024 2024 FY
Q4 2022 $636,727 $45,393 -$112,646 -71% 01 Nov 2022 31 Jan 2023 10-Q 18 Mar 2024 2024 Q3
Q3 2022 $749,373 $177,996 +$42,776 +32% 01 Aug 2022 31 Oct 2022 10-Q 15 Dec 2023 2024 Q2
Q2 2022 $706,597 $159,273 +$15,660 +11% 01 May 2022 31 Jul 2022 10-Q 18 Sep 2023 2024 Q1
Q1 2022 $690,937 $254,065 -$66,208 -21% 01 Feb 2022 30 Apr 2022 10-K 31 Jul 2023 2023 FY
Q4 2021 $757,145 $158,039 -$16,049 -9.2% 01 Nov 2021 31 Jan 2022 10-Q 16 Mar 2023 2023 Q3
Q3 2021 $773,194 $135,220 -$16,094 -11% 01 Aug 2021 31 Oct 2021 10-Q 14 Dec 2022 2022 Q2
Q2 2021 $789,288 $143,613 -$126,961 -47% 01 May 2021 31 Jul 2021 10-Q 14 Sep 2022 2023 Q1
Q1 2021 $916,249 $320,273 +$222,618 +228% 01 Feb 2021 30 Apr 2021 10-K 28 Jul 2022 2022 FY
Q4 2020 $693,631 $174,088 +$60,792 +54% 01 Nov 2020 31 Jan 2021 10-Q 15 Mar 2022 2022 Q3
Q3 2020 $632,839 $151,314 +$133,374 +743% 01 Aug 2020 31 Oct 2020 10-Q 14 Dec 2021 2022 Q2
Q2 2020 $499,465 $270,574 +$198,244 +274% 01 May 2020 31 Jul 2020 10-Q 14 Sep 2021 2022 Q1
Q1 2020 $301,221 $97,655 +$79,642 +442% 01 Feb 2020 30 Apr 2020 10-K 10 Aug 2021 2021 FY
Q4 2019 $221,579 $113,296 +$54,152 +92% 01 Nov 2019 31 Jan 2020 10-Q 12 Mar 2021 2021 Q3
Q3 2019 $167,427 $17,940 -$97,161 -84% 01 Aug 2019 31 Oct 2019 10-Q 11 Dec 2020 2021 Q2
Q2 2019 $264,588 $72,330 -$195,464 -73% 01 May 2019 31 Jul 2019 10-Q 11 Sep 2020 2021 Q1
Q1 2019 $460,052 $18,013 -$234,106 -93% 01 Feb 2019 30 Apr 2019 10-K 13 Aug 2020 2020 FY
Q4 2018 $694,158 $59,144 -$743,420 -93% 01 Nov 2018 31 Jan 2019 10-Q 13 Mar 2020 2020 Q3
Q3 2018 $1,437,578 $115,101 -$400,357 -78% 01 Aug 2018 31 Oct 2018 10-Q 23 Dec 2019 2020 Q2
Q2 2018 $1,837,935 $267,794 -$159,876 -37% 01 May 2018 31 Jul 2018 10-Q 13 Sep 2019 2020 Q1
Q1 2018 $1,997,811 $252,119 +$78,357 +45% 01 Feb 2018 30 Apr 2018 10-K 13 Aug 2019 2019 FY
Q4 2017 $1,919,454 $802,564 +$222,847 +38% 01 Nov 2017 31 Jan 2018 10-Q 14 Mar 2019 2019 Q3
Q3 2017 $1,696,607 $515,458 +$261,690 +103% 01 Aug 2017 31 Oct 2017 10-Q 14 Dec 2018 2019 Q2
Q2 2017 $1,434,917 $427,670 +$252,666 +144% 01 May 2017 31 Jul 2017 10-Q 12 Sep 2018 2019 Q1
Q1 2017 $1,182,251 $173,762 -$63,810 -27% 01 Feb 2017 30 Apr 2017 10-K 20 Jul 2018 2018 FY
Q4 2016 $1,246,061 $579,717 +$5,739 +1% 01 Nov 2016 31 Jan 2017 10-Q 19 Mar 2018 2018 Q3
Q3 2016 $1,240,322 $253,768 -$185,943 -42% 01 Aug 2016 31 Oct 2016 10-Q 14 Dec 2017 2018 Q2
Q2 2016 $1,426,265 $175,004 +$19,326 +12% 01 May 2016 31 Jul 2016 10-Q 13 Sep 2017 2017 Q1
Q1 2016 $1,406,939 $237,572 -$2,617,773 -92% 01 Feb 2016 30 Apr 2016 10-K 27 Jul 2017 2017 FY
Q4 2015 $4,024,712 $573,978 +$300,174 +110% 01 Nov 2015 31 Jan 2016 10-Q 13 Mar 2017 2017 Q3
Q3 2015 $3,724,538 $439,711 +$91,948 +26% 01 Aug 2015 31 Oct 2015 10-Q 02 Dec 2016 2017 Q2
Q2 2015 $3,632,590 $155,678 +$155,678 01 May 2015 31 Jul 2015 10-Q 06 Sep 2016 2017 Q1
Q1 2015 $3,476,912 $2,855,345 01 Feb 2015 30 Apr 2015 10-K 29 Jul 2016 2016 FY
Q4 2014 $273,804 +$273,804 01 Nov 2014 31 Jan 2015 10-Q 08 Mar 2016 2016 Q3
Q3 2014 $347,763 +$347,763 01 Aug 2014 31 Oct 2014 10-Q/A 19 Jan 2016 2016 Q2
Q2 2014 $0 01 May 2014 31 Jul 2014 10-Q/A 19 Jan 2016 2016 Q1
Q4 2013 $0 01 Nov 2013 31 Jan 2014 10-Q 13 Mar 2015 2015 Q3
Q3 2013 $0 01 Aug 2013 31 Oct 2013 10-Q 15 Dec 2014 2015 Q2

PharmaCyte Biotech, Inc. Annual Research and Development Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $438,416 +$30,985 +7.6% 01 May 2024 30 Apr 2025 10-K 11 Aug 2025 2025 FY
2023 $407,431 -$61,105 -13% 01 May 2023 30 Apr 2024 10-K 11 Aug 2025 2025 FY
2022 $468,536 -$222,401 -32% 01 May 2022 30 Apr 2023 10-K 13 Aug 2024 2024 FY
2021 $690,937 -$225,312 -25% 01 May 2021 30 Apr 2022 10-K 31 Jul 2023 2023 FY
2020 $916,249 +$615,028 +204% 01 May 2020 30 Apr 2021 10-K 28 Jul 2022 2022 FY
2019 $301,221 -$158,831 -35% 01 May 2019 30 Apr 2020 10-K 10 Aug 2021 2021 FY
2018 $460,052 -$1,537,759 -77% 01 May 2018 30 Apr 2019 10-K 13 Aug 2020 2020 FY
2017 $1,997,811 +$815,560 +69% 01 May 2017 30 Apr 2018 10-K 13 Aug 2019 2019 FY
2016 $1,182,251 -$224,688 -16% 01 May 2016 30 Apr 2017 10-K 20 Jul 2018 2018 FY
2015 $1,406,939 -$2,069,973 -60% 01 May 2015 30 Apr 2016 10-K 27 Jul 2017 2017 FY
2014 $3,476,912 +$3,153,412 +975% 01 May 2014 30 Apr 2015 10-K 29 Jul 2016 2016 FY
2013 $323,500 +$323,500 01 May 2013 30 Apr 2014 10-K 29 Jul 2016 2016 FY
2012 $0 01 May 2012 30 Apr 2013 10-K/A 19 Jan 2016 2015 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.